

NEW MORCELLATOR FOR CAPTURING AND FRAGMENTING PROSTATE TISSUE



UNMET NEED

Benign prostatic hyperplasia (BPH) is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms (LUTS).

BPH occurs in higher frequencies in the older age groups >50 years and is often accompanied by one or more comorbidities.

BPH is associated with reduced quality of life, impaired psychological well-being, as well as increased health cost.

OUR SOLUTION

Novel improved morcellator system that overcome the current options limitations as low efficacy, undesired tissue extraction, or time consuming procedure. The novel morcellator system is characterized by extendable and retractable clamps, 60mm max clamps opening, a fluid evacuation conduit, and an ablation element with rotary cutting of tungsten wire.

Our asset may overcome most of the drawbacks require of longer surgical interventions and are difficult to resect, which can result in several morbidities.

THE ASSET

Mechanism of action:
Medical device for novel morcellator system

Potential indications:
Avoid possible iatrogenesis and significantly reduce surgical time

IP Protection:
EP22381499

Business model:
Pay per device
B2B, B2A & B2C

OPPORTUNITY

License out

Co-development

MARKET & BUSINESS MODEL

Market size: 200M men

Market value: €10 billion

Market growth:

- ↑ Increasing aging population
- ↑ Rising awareness about prostate cancer and its treatment
- ↑ Growing technological advancements and increasing adoption of minimally invasive procedures

Our solution:

- ✓ Safer and faster than traditional systems
- ✓ Avoid possible iatrogenesis
- ✓ Significantly reduce surgical time
- ✓ Extendable and retractable clamps
- ✓ Fluid evacuation conduit included
- ✓ Ablation element with rotatory cutting of tungsten wire

CONTACT

innovation@igt.p.cat

Innovation & Business Development Unit

